Breaking Finance News

Bayer AG (OTCMKTS:BAYRY) has been upgraded from Neutral to Outperform in a report by Exane BNP Paribas today.

Exane BNP Paribas has upgraded Bayer AG (OTCMKTS:BAYRY) from Neutral to Outperform in a statement released on Monday September 25, 2017.

Having a price of $33.03, Bayer AG (OTCMKTS:BAYRY) traded 0.51% higher on the day. With the last stock price up 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. BAYRY has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. Trade Volume was up over the average, with 38,646 shares of BAYRY changing hands over the typical 0

Recent Performance Chart

Bayer AG (OTCMKTS:BAYRY)

Bayer AG has with a one year low of $22.88 and a one year high of $34.76 and has a market capitalization of $0.

A total of 1 brokerage has issued a ratings update on Bayer AG. One brokerage rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $165.00.

General Company Details For Bayer AG (OTCMKTS:BAYRY)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The Pharmaceuticals division also comprises the radiology business. The Consumer Health segment is engaged in the development, production and marketing of mainly nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products. The Covestro segment is engaged in the development, production and marketing of raw materials for polyurethanes, polycarbonate granules and sheets and raw materials for coatings, adhesives.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.